Complications of the Cephalic Route in Implantable Site Placement in Children
Launched by UNIVERSITY HOSPITAL, ANGERS · Oct 14, 2024
Trial Information
Current as of July 05, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a method called cephalic vein cutdown for placing a special device called a Totally Implantable Venous Access Device (TIVAD) in children. TIVADs are important for children who need long-term intravenous (IV) treatments, like chemotherapy or managing chronic diseases, as they allow safe access to veins without repeatedly poking the skin. The trial aims to understand how well this method works in children and to identify any risks associated with its use.
To be eligible for the study, children under 18 years old who had a TIVAD implanted between 2012 and 2022 can participate, as long as the cephalic vein cutdown was the first method tried for placing the device. Participants will not need to do anything special beyond the usual procedures for TIVAD implantation. The research will help doctors learn more about the effectiveness and safety of this technique, which has not been widely studied in children before.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients under 18 years who underwent TIVAD implantation between 2012 and 2022.
- • Patients for whom cephalic vein cutdown was the first attempted surgical technique for device placement.
- Exclusion Criteria:
- • Patients who previously had a central venous access
About University Hospital, Angers
The University Hospital of Angers is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital leverages its multidisciplinary expertise and state-of-the-art facilities to investigate new therapeutic approaches and improve patient outcomes. Committed to excellence in patient care and medical education, the University Hospital of Angers collaborates with a network of researchers and healthcare professionals to facilitate groundbreaking studies across various medical fields, ensuring rigorous adherence to ethical standards and regulatory compliance. Through its clinical trial initiatives, the institution aims to contribute significantly to the advancement of medical knowledge and the development of effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported